A randomized, double-blind comparison of atomoxetine hydrochloride and placebo for symptoms of attention-deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder.

Trial Profile

A randomized, double-blind comparison of atomoxetine hydrochloride and placebo for symptoms of attention-deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2012 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry.
    • 11 Nov 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top